Literature DB >> 31006086

Management of postoperative chylous ascites after surgery for ovarian cancer: a single-institution experience.

Giuseppe Scaletta1, Lorena Quagliozzi1, Stefano Cianci2, Virginia Vargiu1, Maria Cristina Mele3, Giovanni Scambia1, Anna Fagotti1.   

Abstract

Postoperative chylous ascites is a rare complication from operative trauma to the cisterna chyli or lymphatic vessels in the retroperitoneum. In the present study, we aimed to identify the incidence of postoperative chylous ascites in patients treated for ovarian cancer and to describe its management. We retrospectively reviewed all patients submitted to surgery for ovarian cancer at our Institution from October 2016 to November 2018. We analyzed the clinicopathological features, including the primary tumor histology, stage, grade, surgical procedure, median number of harvested pelvic and para-aortic lymph nodes. We described our experience in the diagnosis and management of chylous ascites. Five hundred and forty-six patients were submitted to surgery for ovarian cancer and 298 patients received pelvic and/or para-aortic lymphadenectomy. Chylous ascites occurred in 8 patients with an incidence of 1.4% in the overall population and a 2.68% among patients receiving lymphadenectomy. All patients received total parenteral nutrition (TPN) with Olimel N4E 2000 mL (Baxter®) and somatostatin therapy with 0.2 mL per 3 times/day for a median of 9 days (range 7-11). Median hospital stay was 15 days (range 7-16). All patients were successfully managed conservatively and none required surgical correction. Conservative management of chylous ascites with TPN, somatostatin and paracentisis is feasible and effective. These data should be confirmed by prospective multicentric studies.

Entities:  

Keywords:  Chylous ascites; Ovarian cancer; Personalized medicine; Total parenteral nutrition

Mesh:

Substances:

Year:  2019        PMID: 31006086     DOI: 10.1007/s13304-019-00656-x

Source DB:  PubMed          Journal:  Updates Surg        ISSN: 2038-131X


  50 in total

1.  Chylous ascites: analysis of 24 patients.

Authors:  Gokhan Tulunay; Isin Ureyen; Taner Turan; Alper Karalok; Duygu Kavak; Nejat Ozgul; Reyhan Ocalan; Omer Lutfi Tapisiz; Nurettin Boran; Mehmet Faruk Kose
Journal:  Gynecol Oncol       Date:  2012-06-21       Impact factor: 5.482

2.  Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: A Large, Single-Institution Experience.

Authors:  Valerio Gallotta; Carmine Conte; Maria Teresa Giudice; Camilla Nero; Giuseppe Vizzielli; Salvatore Gueli Alletti; Stefano Cianci; Claudio Lodoli; Andrea Di Giorgio; Agostino Maria De Rose; Anna Fagotti; Giovanni Scambia; Gabriella Ferrandina
Journal:  J Minim Invasive Gynecol       Date:  2017-11-13       Impact factor: 4.137

3.  Does HE4 have a role as biomarker in the recurrence of ovarian cancer?

Authors:  Francesco Plotti; Stella Capriglione; Corrado Terranova; Roberto Montera; Alessia Aloisi; Patrizio Damiani; Ludovico Muzii; Giuseppe Scaletta; Pierluigi Benedetti-Panici; Roberto Angioli
Journal:  Tumour Biol       Date:  2012-08-09

Review 4.  Management of endometrial, ovarian and cervical cancer in the elderly: current approach to a challenging condition.

Authors:  Salvatore Giovanni Vitale; Stella Capriglione; Gabriella Zito; Salvatore Lopez; Ferdinando Antonio Gulino; Federica Di Guardo; Amerigo Vitagliano; Marco Noventa; Valentina Lucia La Rosa; Fabrizio Sapia; Gaetano Valenti; Agnese Maria Chiara Rapisarda; Isabel Peterlunger; Diego Rossetti; Antonio Simone Laganà
Journal:  Arch Gynecol Obstet       Date:  2018-12-12       Impact factor: 2.344

Review 5.  Tumor markers of uterine cervical cancer: a new scenario to guide surgical practice?

Authors:  Gaetano Valenti; Salvatore Giovanni Vitale; Alessandro Tropea; Antonio Biondi; Antonio Simone Laganà
Journal:  Updates Surg       Date:  2017-09-16

6.  Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy.

Authors:  Salvatore Caruso; Stefano Cianci; Salvatore Giovanni Vitale; Valentina Fava; Silvia Cutello; Antonio Cianci
Journal:  Eur J Contracept Reprod Health Care       Date:  2018-02-13       Impact factor: 1.848

7.  Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Authors:  M Petrillo; P De Iaco; S Cianci; M Perrone; B Costantini; C Ronsini; G Scambia; A Fagotti
Journal:  Ann Surg Oncol       Date:  2015-12-29       Impact factor: 5.344

8.  Preoperative local staging of endometrial cancer: the challenge of imaging techniques and serum biomarkers.

Authors:  Roberto Angioli; Francesco Plotti; Stella Capriglione; Giuseppe Scaletta; Nella Dugo; Alessia Aloisi; Claudia Lucia Piccolo; Riccardo Del Vescovo; Corrado Terranova; Bruno Beomonte Zobel
Journal:  Arch Gynecol Obstet       Date:  2016-08-17       Impact factor: 2.344

Review 9.  Surgical treatment of high stage endometrial cancer: current perspectives.

Authors:  Salvatore Giovanni Vitale; Gaetano Valenti; Ferdinando Antonio Gulino; Pietro Cignini; Antonio Biondi
Journal:  Updates Surg       Date:  2016-01-29

10.  Isoflavones, calcium, vitamin D and inulin improve quality of life, sexual function, body composition and metabolic parameters in menopausal women: result from a prospective, randomized, placebo-controlled, parallel-group study.

Authors:  Salvatore Giovanni Vitale; Salvatore Caruso; Agnese Maria Chiara Rapisarda; Stefano Cianci; Antonio Cianci
Journal:  Prz Menopauzalny       Date:  2018-04-11
View more
  2 in total

Review 1.  Lymphatic Interventions in the Cancer Patient.

Authors:  Eslam Wassal Youssef; Ahmed Aly; Akshaar Brahmbhatt; Amgad Moussa; Ernesto Santos
Journal:  Curr Oncol Rep       Date:  2022-05-31       Impact factor: 5.945

2.  Risk Factors for Anastomotic Leakage in Advanced Ovarian Cancer Surgery: A Large Single-Center Experience.

Authors:  Barbara Costantini; Virginia Vargiu; Francesco Santullo; Andrea Rosati; Matteo Bruno; Valerio Gallotta; Claudio Lodoli; Rossana Moroni; Fabio Pacelli; Giovanni Scambia; Anna Fagotti
Journal:  Ann Surg Oncol       Date:  2022-04-18       Impact factor: 4.339

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.